Skip to main content

Day: January 5, 2026

MiniLuxe Announces Approval of Amendments to Equity Incentive Plan

Boston, MA, Jan. 05, 2026 (GLOBE NEWSWIRE) — MiniLuxe Holding Corp. (TSXV: MNLX) — MiniLuxe, the pioneer in clean nail care and ethical nail services, announces that on November 20, 2025, its shareholders approved certain amendments to the Company’s equity incentive plan. The amendments converted the plan from a rolling 10% plan to a fixed plan of up to 20% and increased the number of shares available for issuance thereunder to 33,493,526 shares, representing 20% of the aggregate number of subordinate voting shares and proportionate voting shares outstanding as of the date of implementation of the amended plan. Additional details regarding the amended equity incentive plan are set out in the Company’s management information circular dated October 16, 2025, which is available on the Company’s profile on SEDAR+. About MiniLuxeMiniLuxe...

Continue reading

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

– Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare – – Obexelimab also met and demonstrated statistically significant activity on all four key secondary efficacy endpoints – – Obexelimab was well tolerated and no new safety signals were observed – – Zenas anticipates submitting a Biologics License Application (BLA) to the FDA in the second quarter of 2026 and a Marketing Authorization Application (MAA) to the EMA in the second half of 2026 – – Zenas to host a conference call today, January 5, 2026, at 8:00 a.m. ET – WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global...

Continue reading

Prospect Credit REIT Achieves 13.35% Annualized Total Return Versus 6.28% Stanger-Tracked Non-Traded REIT Average Through Q3 2025

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) — Since commencement of operations through September 30, 2025, Prospect Credit REIT, LLC (“PCRED”), a non-traded real estate credit fund, achieved an annualized total return of 13.35% to investors. Over this period, PCRED’s total return performance has been higher than the average total return of 6.28% of the 35 total registered and private non-traded net asset value real estate investment trusts (“NAV REITs”) tracked by Robert A. Stanger & Company, Inc. (“Stanger”). Total return is calculated based on reported total distributions paid to investors for the period plus the reported change in net asset value attributable to investment operations, divided by ending net asset value and less fees. The NAV REITs tracked by Stanger are primarily equity-focused NAV REITs, which...

Continue reading

Transocean Ltd. Announces Contract Award and Extension Totaling $168 Million

STEINHAUSEN, Switzerland, Jan. 05, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced a contract award and an extension, respectively, for two of its drilling rigs. Together, the fixtures represent approximately $168 million of firm backlog. In Brazil, the Deepwater Mykonos was awarded a contract with bp. The estimated 302-day campaign is expected to begin in the third quarter of 2026 and contribute approximately $120 million in backlog, excluding additional services and compensation for mobilization and demobilization. In Norway, three one-well options have been exercised for the Transocean Enabler. The incremental 105 days of work, which is in direct continuation of the rig’s current activity, is expected to contribute approximately $48 million in backlog and commits the Enabler through September...

Continue reading

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial Magnetic Stimulation (TMS) machines nationwide. Program will unite common treatment protocols and clinical training with neurocare expertise in neuromodulation technology and NRx Pharmaceuticals neuroplastic drug development program. Pilot program with a state first-responder agency has demonstrated high rates of success in combining TMS, neuroplastic drug treatment, hyperbaric oxygen, and psychotherapy to achieve remission from PTSD and Depression in First Responders. neurocare and NRx look forward to offering an integrated treatment program to patients and payers within driving distance of any American home by year-end 2026.WILMINGTON, Del. and MUNICH, Jan. 05, 2026 (GLOBE NEWSWIRE)...

Continue reading

LYB to discuss fourth-quarter results Friday, Jan. 30, 2026

HOUSTON and LONDON, Jan. 05, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB), a leader in the global chemical industry, will announce its fourth-quarter 2025 financial results before the U.S. market opens Friday, Jan. 30, followed by a webcast and teleconference to discuss the results at 11 a.m. EST. Teleconference and webcast detailsFriday, January 30, 202611 a.m. ESTHosted by David Kinney, head of investor relationsAccess the webcast 10 to 15 minutes prior to the start of the call at www.lyb.com/earnings. Toll-free teleconference dial-in numbersParticipant/Guest toll-free: 877-407-8029Participant/Guest toll: 201-689-8029Participant/Guest: CallMe link Presentation slidesPresentation slides will be available at the time of the teleconference and afterward at www.lyb.com/earnings. Replay informationA replay of the call will...

Continue reading

Scorpio Tankers Inc. Announces Time Charter-Out Agreements

MONACO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has entered into agreements to time charter-out the 2015 built LR2 product tankers, STI Rose and STI Alexis. The term of each agreement is five years at a rate of $29,000 per vessel per day. These time charters are expected to commence in the first quarter of 2026. About Scorpio Tankers Inc. Scorpio Tankers Inc. is a provider of marine transportation of petroleum products worldwide. Scorpio Tankers Inc. currently owns or lease finances 93 product tankers (37 LR2 tankers, 42 MR tankers and 14 Handymax tankers) with an average age of 9.8 years. The Company has entered into agreements to sell three LR2 product tankers which are expected to close in the first quarter of 2026. The Company has also reached...

Continue reading

Brookfield Business Partners to Host Fourth Quarter 2025 Results Conference Call

Date: Friday, January 30, 2026Time: 10:00 a.m. (Eastern Time) BROOKFIELD, NEWS, Jan. 05, 2026 (GLOBE NEWSWIRE) — Brookfield Business Partners will host its Fourth Quarter 2025 Conference Call & Webcast on Friday, January 30, 2026 at 10:00 a.m. (ET) to discuss results and current business initiatives. Results will be released on Friday, January 30, 2026 prior to 8:00 a.m. (ET) and will be available following the release on our website at https://bbu.brookfield.com. Participants can join by conference call or webcast: Conference CallPlease pre-register: BBU2025Q4ConferenceCall Upon registering, you will be emailed a dial-in number and unique PIN. This process will bypass the operator and avoid the queue.WebcastPlease join and register by webcast: BBU2025Q4Webcast A replay of the webcast will be available on our website.Brookfield...

Continue reading

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline...

Continue reading

Share repurchase programme: Transactions of week 1 2026

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 3,015,948 657.98 1,984,433,41829 December 2025 14,912 864.42 12,890,25830...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.